MDxHealth SA (NASDAQ:MDXH) Short Interest Update

Key Points

• Short interest for MDxHealth SA decreased by 33.8% in September, dropping to 41,100 shares from 62,100 shares in August, with only 0.1% of the stock currently short sold.
• Several hedge funds have increased their positions in MDxHealth, with Delta Investment Management LLC boosting its stake by a remarkable 459.1%.
• MDxHealth's stock is currently valued at $4.73, down 1.7%, with a negative PE ratio of -5.38 and an anticipated earnings per share of -1.15 for the fiscal year.

MDxHealth SA (NASDAQ:MDXH - Get Free Report) was the recipient of a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 41,100 shares, a decrease of 33.8% from the August 31st total of 62,100 shares. Based on an average daily volume of 131,700 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.1% of the shares of the stock are short sold. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 131,700 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Trading of MDxHealth

A number of hedge funds have recently made changes to their positions in MDXH. AWM Investment Company Inc. increased its stake in MDxHealth by 10.6% during the 1st quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company's stock worth $7,414,000 after buying an additional 499,992 shares during the period. Perkins Capital Management Inc. raised its stake in shares of MDxHealth by 20.1% in the 1st quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company's stock valued at $1,678,000 after purchasing an additional 198,000 shares in the last quarter. Delta Investment Management LLC increased its holdings in shares of MDxHealth by 459.1% in the 1st quarter. Delta Investment Management LLC now owns 190,100 shares of the company's stock valued at $270,000 after acquiring an additional 156,100 shares during the last quarter. FreeGulliver LLC bought a new stake in shares of MDxHealth during the 2nd quarter valued at about $273,000. Finally, Castleview Partners LLC bought a new stake in shares of MDxHealth in the 1st quarter worth approximately $48,000.

MDxHealth Trading Down 1.7%

NASDAQ:MDXH traded down $0.08 on Monday, hitting $4.73. 143,031 shares of the stock were exchanged, compared to its average volume of 103,224. The stock has a market cap of $223.67 million, a PE ratio of -5.38 and a beta of 1.65. MDxHealth has a fifty-two week low of $1.35 and a fifty-two week high of $4.94. The company has a current ratio of 1.31, a quick ratio of 1.22 and a debt-to-equity ratio of 13.81. The stock has a fifty day moving average of $3.47 and a 200-day moving average of $2.46.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The business had revenue of $26.60 million for the quarter, compared to analyst estimates of $26.60 million. MDxHealth had a negative net margin of 34.98% and a negative return on equity of 374.98%. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. As a group, equities analysts expect that MDxHealth will post -1.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on MDXH. Craig Hallum started coverage on MDxHealth in a report on Thursday, July 17th. They issued a "buy" rating and a $8.00 price target for the company. Wall Street Zen upgraded shares of MDxHealth to a "hold" rating in a report on Saturday, August 30th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of MDxHealth in a research report on Saturday, September 27th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.